Uroplasty Expands Marketing Program for Urology... ( - Program To Help Create Awareness o...)

Uroplasty Expands Marketing Program for Urology Practices

Date:1/17/2008

- Program To Help Create Awareness of a Non-Invasive Treatment Option for

Overactive Bladder Symptoms -

MINNEAPOLIS, Jan. 17 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) today announced the expansion of its CO-OP marketing program to customers of its Urgent PC(R) neuromodulation system for the treatment of overactive bladder (OAB) symptoms. Uroplasty offers this marketing program to customers who wish to promote the availability in their practice of this leading non-surgical, office-based treatment option.

"This is the right time to offer an expanded marketing program to our fast-growing base of customers," said David B. Kaysen, Uroplasty's President and CEO. "In the quarter ended December 31, 2007 we had over 300 active customers in the United States, consisting primarily of urologists and urogynecologists, who purchased our Urgent PC neuromodulation system or additional lead sets. This represents in excess of a 150% increase from 119 active customers we had in our fourth fiscal quarter ended March 31, 2007. Our expanded marketing program gives our customers more options to enhance their practice, and market the benefits and availability of the Urgent PC system to their patients."

Kaysen continued, "Our focus in the U.S. is to both expand our new customer base and increase our revenue from our existing customer base. We believe this marketing program, an important part of our growth strategy, will allow our customers to increasingly incorporate the Urgent PC system as part of the treatment option they offer to their patients."

Program participants, working closely with Uroplasty, select a marketing program suitable for their practice from a menu of options which includes local media print advertising, patient and physician education seminars, direct mail campaign, and local radio advertising. Uroplasty and the participant share the marketing program costs in proportion to the benefit each receives fr
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
2. Uroplasty to Host Second Quarter Conference Call on November 1
3. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
4. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
5. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
6. Rohm and Haas Expands in India
7. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
8. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
9. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
10. Specialty Blades, Inc. Expands Management Team With New VP Engineering
11. CRH Medical expands Las Vegas operations

Post Your Comments:

(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given

(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for

(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W

(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s

[0] Salon Leau to Host 'Cuts for a Cause' to Raise Funds and Spread the Word About Childhood Terminal Illnesses [0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification [0] Distributor Announces New Applications for Wind Turbines [0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children

...daq: XTNT ) today reported financial results for ...7., The company reported a net loss and net loss ...on, or $0.52 per share, for the fourth quarter,of ...mpany,s net loss per share attributable to common ...

... same results, analysis shows , , TUESDAY,...cular advantage to any single treatment for acute ...ion that carries with it a high risk of death, Can...or another, according to a report in the Feb. 20 ...

... way to spot hearing problems, study finds, , ...s may not just be a window to the soul, they may a...r senses. , A new study reports that the eyes can ... young children and in people who can,t actively t...

...tive isotopes for peacetime uses at Oak Ridge Nati...al Historic Chemical Landmark by the American Chem...enn., on March 6. , Bruce E. Bursten, Ph.D., pre...s, which began in 1946, demonstrated the peaceful ...

... Hospital, WALLA WALLA, Wash., Feb. 19 Secretary...today the Department of,Veterans Affairs (VA) will...on facility focused on mental health at the Walla ...ortance of mental,health as an issue for our veter...

...ered physical or sexual abuse as children spend up...ts, according to a long-term study of more than 3,...these women used health services at significantly ...quences from abuse that occurred decades ago, said...

Other Medicine News:Health News:XTENT Announces 2007 Financial Results 2 Health News:XTENT Announces 2007 Financial Results 3 Health News:XTENT Announces 2007 Financial Results 4 Health News:XTENT Announces 2007 Financial Results 5 Health News:XTENT Announces 2007 Financial Results 6 Health News:No Difference Found in Treatments for Acute Kidney Failure 2 Health News:No Difference Found in Treatments for Acute Kidney Failure 3 Health News:Eyes a Window to Hearing Loss? 2 Health News:Eyes a Window to Hearing Loss? 3 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3 Health News:Women who suffered child abuse spend more on health care 2 Health News:Women who suffered child abuse spend more on health care 3

XTENT Announces 2007 Financial Results No Difference Found in Treatments for Acute Kidney Failure Eyes a Window to Hearing Loss?Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark VA Secretary Announces New Walla Walla Facility Women who suffered child abuse spend more on health care

(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab

(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,

(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square

Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3 AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1 AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 1 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 2 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 3 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 4 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 5 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 6 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 7 Child Food Allergies on the Rise in U S 61410 1 Child Food Allergies on the Rise in U S 61410 2 Child Food Allergies on the Rise in U S 61410 3

[0] US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder [0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects [0] BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark

...nificant Reduction in Relapse Rate , , - Secondar... of Patients Relapse-Free and Disability Progressi...e Tablets Planned for mid-2009 , , SEATTLE and GE...KGaA, announced today detailed results of the two-... III trial using Cladribine Tablets (Merck Serono,...

...y and safety for extended release and immediate re...ril 29 /PRNewswire/ -- New findings from two dou...ty and tolerability of pramipexole dihydrochloride...ation, for the treatment of Parkinson,s disease (P...emy of Neurology (AAN) 61st Annual Meeting in Seat...

Other Medicine Technology:Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 2 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 3 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 4 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 5 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 6 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 7 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

Full Body Girdle V-1655

Body Suit w/Bra above knee, Front Closure

Compression Vest V-640

Male Compression Vest Binder

Medicine Products:

Full Body Girdle V-1655 Body Suit w/Bra above knee, Front Closure Compression Vest V-640 Male Compression Vest Binder

Uroplasty Expands Marketing Program for Urology...( - Program To Help Create Awareness o...),Health